Compendium of Cancer Genome Aberrations

Changes

Volunteer Assignments and Opportunities (view source)

Revision as of 12:59, 7 August 2020

559 bytes added ,  12:59, 7 August 2020
no edit summary
Line 3: Line 3:  
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
 
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
 
|-
 
|-
−
!'''Disease'''!!'''Page Type'''!!'''Author (Date Assigned)'''!!'''Associate Editor'''
+
!'''Disease'''!!'''Page Type'''!!'''Author'''
 +
!'''Date Assigned'''!!'''Associate Editor'''
 
!Author Content Pending or Complete (Date Completed)
 
!Author Content Pending or Complete (Date Completed)
 
!Editor Reviewed (Date)
 
!Editor Reviewed (Date)
Line 9: Line 10:  
|-
 
|-
 
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
 
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
 +
|
 
|Fabiola Quintero-Rivera (FQR)
 
|Fabiola Quintero-Rivera (FQR)
 
|PENDING
 
|PENDING
Line 16: Line 18:  
|    Chronic Myeloid  Leukemia (CML), BCR-ABL1-Positive||Disease
 
|    Chronic Myeloid  Leukemia (CML), BCR-ABL1-Positive||Disease
 
|Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera
 
|Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 23: Line 26:  
|    Chronic Neutrophilic  Leukemia (CNL)||Disease
 
|    Chronic Neutrophilic  Leukemia (CNL)||Disease
 
|Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
 
|Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 30: Line 34:  
|    Polycythaemia Vera  (PV)||Disease
 
|    Polycythaemia Vera  (PV)||Disease
 
|Gokce A. Toruner
 
|Gokce A. Toruner
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 37: Line 42:  
|    Primary Myelofibrosis  (PMF)||Disease
 
|    Primary Myelofibrosis  (PMF)||Disease
 
|T. Niroshi  Senaratne
 
|T. Niroshi  Senaratne
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 44: Line 50:  
|    Essential  Thrombocythaemia (ET)||Disease
 
|    Essential  Thrombocythaemia (ET)||Disease
 
|Rebecca Smith (trainee) + faculty TBD
 
|Rebecca Smith (trainee) + faculty TBD
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 51: Line 58:  
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
 
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
 
|Mark Evans (trainee), Fabiola Quintero-Rivera
 
|Mark Evans (trainee), Fabiola Quintero-Rivera
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 58: Line 66:  
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
 
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
 
|Mark Evans (trainee)+ Fabiola Quintero-Rivera
 
|Mark Evans (trainee)+ Fabiola Quintero-Rivera
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 63: Line 72:  
|
 
|
 
|-
 
|-
−
|'''''Mastocytosis'''''||'''''Overview'''''|| ||FQR
+
|'''''Mastocytosis'''''||'''''Overview'''''||
 +
| ||FQR
 
|
 
|
 
|
 
|
Line 70: Line 80:  
|    Cutaneous  Mastocytosis||Disease
 
|    Cutaneous  Mastocytosis||Disease
 
|Thuy Phung
 
|Thuy Phung
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 77: Line 88:  
|    Systemic Mastocytosis||Disease
 
|    Systemic Mastocytosis||Disease
 
|Shashi Shetty
 
|Shashi Shetty
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 84: Line 96:  
|    Mast Cell Sarcoma||Disease
 
|    Mast Cell Sarcoma||Disease
 
|Thuy Phung
 
|Thuy Phung
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 90: Line 103:  
|-
 
|-
 
|'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff
 
|'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 96: Line 110:  
|-
 
|-
 
|    Myeloid/Lymphoid  Neoplasms with PDGFRA Rearrangement||Disease||Jay Alden  (trainee) +Daynna J.Wolff
 
|    Myeloid/Lymphoid  Neoplasms with PDGFRA Rearrangement||Disease||Jay Alden  (trainee) +Daynna J.Wolff
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 102: Line 117:  
|-
 
|-
 
|    Myeloid/Lymphoid  Neoplasms with PDGFRB Rearrangement||Disease||Christopher Sullivan (trainee) + Daynna J.Wolff
 
|    Myeloid/Lymphoid  Neoplasms with PDGFRB Rearrangement||Disease||Christopher Sullivan (trainee) + Daynna J.Wolff
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 108: Line 124:  
|-
 
|-
 
|    Myeloid/Lymphoid  Neoplasms with FGFR1 Rearrangement||Disease||Yanna Ding
 
|    Myeloid/Lymphoid  Neoplasms with FGFR1 Rearrangement||Disease||Yanna Ding
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 114: Line 131:  
|-
 
|-
 
|    Myeloid/Lymphoid  Neoplasms with PCM1-JAK2||Disease||Jessica Snider (trainee) + Daynna J.Wolff
 
|    Myeloid/Lymphoid  Neoplasms with PCM1-JAK2||Disease||Jessica Snider (trainee) + Daynna J.Wolff
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 122: Line 140:  
|Disease
 
|Disease
 
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
 
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 130: Line 149:  
|Disease
 
|Disease
 
|Lauren R. Crowson (trainee) + Daynna J. Wolff
 
|Lauren R. Crowson (trainee) + Daynna J. Wolff
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 136: Line 156:  
|-
 
|-
 
|'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''||Linsheng Zhang
 
|'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''||Linsheng Zhang
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 142: Line 163:  
|-
 
|-
 
|    Chronic  Myelomonocytic Leukemia (CMML)||Disease||Linsheng Zhang
 
|    Chronic  Myelomonocytic Leukemia (CMML)||Disease||Linsheng Zhang
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 148: Line 170:  
|-
 
|-
 
|    Atypical Chronic  Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease||Linsheng Zhang
 
|    Atypical Chronic  Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease||Linsheng Zhang
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 154: Line 177:  
|-
 
|-
 
|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
 
|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 160: Line 184:  
|-
 
|-
 
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
 
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 166: Line 191:  
|-
 
|-
 
|     Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease||Ruth MacKinnon
 
|     Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease||Ruth MacKinnon
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 172: Line 198:  
|-
 
|-
 
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
 
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
 +
|
 
|FQR
 
|FQR
 
|
 
|
Line 178: Line 205:  
|-
 
|-
 
|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
 
|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 184: Line 212:  
|-
 
|-
 
|    Myelodysplastic  Syndrome with Ring Sideroblasts (MDS-RS)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 
|    Myelodysplastic  Syndrome with Ring Sideroblasts (MDS-RS)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 190: Line 219:  
|-
 
|-
 
|    Myelodysplastic  Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 
|    Myelodysplastic  Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 196: Line 226:  
|-
 
|-
 
|    Myelodysplastic  syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
 
|    Myelodysplastic  syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 202: Line 233:  
|-
 
|-
 
|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
 
|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 208: Line 240:  
|-
 
|-
 
|    Myelodysplastic  Syndrome (MDS) with Isolated del(5q)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 
|    Myelodysplastic  Syndrome (MDS) with Isolated del(5q)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|Complete
 
|Complete
Line 214: Line 247:  
|-
 
|-
 
|    Myelodysplastic  Syndrome (MDS), Unclassifiable||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 
|    Myelodysplastic  Syndrome (MDS), Unclassifiable||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 220: Line 254:  
|-
 
|-
 
|    Refractory Cytopenia  of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
 
|    Refractory Cytopenia  of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
 +
|
 
|FQR
 
|FQR
 
|PENDING
 
|PENDING
Line 225: Line 260:  
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
Line 231: Line 267:  
|-
 
|-
 
|'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident)
 
|'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident)
 +
|
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Complete
 
|Complete
Line 236: Line 273:  
|
 
|
 
|-
 
|-
−
|'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''||Ying  Zou||JH / MS
+
|'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''||Ying  Zou
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease||Daynna Wolff+Matthew Kilpatrick (Path Resident)||JH / MS
+
|    Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease||Daynna Wolff+Matthew Kilpatrick (Path Resident)
 +
| ||JH / MS
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease||Fei Yang||JH / MS
+
|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease||Fei Yang
 +
| ||JH / MS
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Myeloid Neoplasms with Germline RUNX1  Mutation||Disease||Malini Sathanoori||JH / MS
+
|    Myeloid Neoplasms with Germline RUNX1  Mutation||Disease||Malini Sathanoori
 +
| ||JH / MS
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Myeloid Neoplasms with Germline ANKRD26  Mutation||Disease||Fei Yang||JH / MS
+
|    Myeloid Neoplasms with Germline ANKRD26  Mutation||Disease||Fei Yang
 +
| ||JH / MS
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Myeloid Neoplasms with Germline ETV6  Mutation||Disease||Ying Zou||JH / MS
+
|    Myeloid Neoplasms with Germline ETV6  Mutation||Disease||Ying Zou
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Myeloid Neoplasms with Germline GATA2  Mutation||Disease||Daynna Wolff+ Alexandria Avery (Path Resident)||JH / MS
+
|    Myeloid Neoplasms with Germline GATA2  Mutation||Disease||Daynna Wolff+ Alexandria Avery (Path Resident)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
Line 272: Line 316:  
|-
 
|-
 
|'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||Daynna Wolff+ Dan Wang (trainee)
 
|'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||Daynna Wolff+ Dan Wang (trainee)
 +
|
 
|JH / MS
 
|JH / MS
 
|Complete
 
|Complete
Line 277: Line 322:  
|
 
|
 
|-
 
|-
−
|    Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease||Christine Bryke||JH / MS
+
|    Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease||Christine Bryke
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia with  inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease||Christine Bryke||JH / MS
+
|    Acute Myeloid Leukemia with  inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease||Christine Bryke
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Promyelocytic Leukemia (APL) with  PML-RARA||Disease||Shashi Shetty||JH / MS
+
|    Acute Promyelocytic Leukemia (APL) with  PML-RARA||Disease||Shashi Shetty
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease||Shashi Shetty||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease||Shashi Shetty
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  t(6;9)(p23;q34.1); DEK-NUP214||Disease||Jennelle Hodge||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  t(6;9)(p23;q34.1); DEK-NUP214||Disease||Jennelle Hodge
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease||Gordana Raca||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease||Gordana Raca
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|Need permission for figure?  Update WHO?
 
|Need permission for figure?  Update WHO?
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML)  Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease||Jennelle Hodge||JH / MS
+
|    Acute Myeloid Leukemia (AML)  Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease||Jennelle Hodge
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|Add WHO reference
 
|Add WHO reference
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Conboy (Monash Health)||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Conboy (Monash Health)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with  Mutated RUNX1||Disease||Daynna Wolff+Iris Martin (Path Resident)||JH / MS
+
|    Acute Myeloid Leukemia (AML) with  Mutated RUNX1||Disease||Daynna Wolff+Iris Martin (Path Resident)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease||Fei Yang||JH / MS
+
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease||Fei Yang
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Therapy-Related Myeloid Neoplasms||Disease||Shashi Shetty + Shawn A. Silver (resident)||JH / MS
+
|Therapy-Related Myeloid Neoplasms||Disease||Shashi Shetty + Shawn A. Silver (resident)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|Check reference format
 
|Check reference format
 
|-
 
|-
−
|''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''||Anwar Iqbal||JH / MS
+
|''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''||Anwar Iqbal
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease||Fabiola Quintero-Rivera and Celeste Eno (fellow)||JH / MS
+
|    Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease||Fabiola Quintero-Rivera and Celeste Eno (fellow)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   Acute Myeloid Leukemia (AML) without Maturation||Disease||Jennelle Hodge||JH / MS
+
|   Acute Myeloid Leukemia (AML) without Maturation||Disease||Jennelle Hodge
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myeloid Leukemia (AML) with Maturation||Disease||Jennelle Hodge||JH / MS
+
|    Acute Myeloid Leukemia (AML) with Maturation||Disease||Jennelle Hodge
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Myelomonocytic Leukemia||Disease||Fei Yang||JH / MS
+
|    Acute Myelomonocytic Leukemia||Disease||Fei Yang
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Monoblastic and Monocytic Leukemia||Disease||Fei Yang||JH / MS
+
|    Acute Monoblastic and Monocytic Leukemia||Disease||Fei Yang
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Pure Erythroid Leukemia||Disease||Ash  Yenamandra||JH / MS
+
|    Pure Erythroid Leukemia||Disease||Ash  Yenamandra
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Megakaryoblastic Leukemia (AMKL)||Disease||Fei Yang||JH / MS
+
|    Acute Megakaryoblastic Leukemia (AMKL)||Disease||Fei Yang
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Basophilic Leukemia||Disease||Ash Yenamandra||JH / MS
+
|    Acute Basophilic Leukemia||Disease||Ash Yenamandra
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute Panmyelosis with Myelofibrosis||Disease||Ying Zou and Jialing Huang (MGP fellow)||JH / MS
+
|    Acute Panmyelosis with Myelofibrosis||Disease||Ying Zou and Jialing Huang (MGP fellow)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Myeloid Sarcoma||Disease||Fabiola Quintero-Rivera||JH / MS
+
|Myeloid Sarcoma||Disease||Fabiola Quintero-Rivera
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''||Patty  Greipp||JH / MS
+
|'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''||Patty  Greipp
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|Need permission for figure?
 
|Need permission for figure?
 
|-
 
|-
−
|    Transient Abnormal Myelopoiesis (TAM)  Associated with Down Syndrome||Disease||Linda Cooley||JH / MS
+
|    Transient Abnormal Myelopoiesis (TAM)  Associated with Down Syndrome||Disease||Linda Cooley
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Myeloid Leukemia Associated with Down  Syndrome||Disease||Linda Cooley||JH / MS
+
|    Myeloid Leukemia Associated with Down  Syndrome||Disease||Linda Cooley
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease||Daynna Wolff+Hao Liu (Path Resident)||JH / MS
+
|Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease||Daynna Wolff+Hao Liu (Path Resident)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''||Hui Chen/ Jennelle Hodge||JH / MS
+
|'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''||Hui Chen/ Jennelle Hodge
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Acute  Undifferentiated Leukemia||Disease||Shashi Shetty + Amelia Nakanishi (resident)||JH / MS
+
|    Acute  Undifferentiated Leukemia||Disease||Shashi Shetty + Amelia Nakanishi (resident)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|Check reference format
 
|Check reference format
 
|-
 
|-
−
|    Mixed Phenotype Acute  Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease||Tracy Tucker||JH / MS
+
|    Mixed Phenotype Acute  Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease||Tracy Tucker
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Mixed Phenotype Acute Leukemia (MPAL)  with t(v;11q23.3); KMT2A Rearranged||Disease||Tracy Tucker||JH / MS
+
|    Mixed Phenotype Acute Leukemia (MPAL)  with t(v;11q23.3); KMT2A Rearranged||Disease||Tracy Tucker
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Mixed Phenotype Acute Leukemia (MPAL),  B/Myeloid, Not Otherwise Specified||Disease||Shashi Shetty + Priyatharsini Nirmalanantham (resident)||JH / MS
+
|    Mixed Phenotype Acute Leukemia (MPAL),  B/Myeloid, Not Otherwise Specified||Disease||Shashi Shetty + Priyatharsini Nirmalanantham (resident)
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|Check reference format
 
|Check reference format
 
|-
 
|-
−
|    Mixed Phenotype Acute Leukemia (MPAL),  T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera||JH / MS
+
|    Mixed Phenotype Acute Leukemia (MPAL),  T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
 +
| ||JH / MS
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    ??Mixed-Phenotype Acute Leukaemia, Not  Otherwise Specified (NOS), Rare Types||Disease|| ||JH / MS
+
|    ??Mixed-Phenotype Acute Leukaemia, Not  Otherwise Specified (NOS), Rare Types||Disease||
 +
| ||JH / MS
 
|??
 
|??
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    ??Acute Leukaemias of Ambiguous Lineage,  Not Otherwise Specified (NOS)||Disease|| ||JH / MS
+
|    ??Acute Leukaemias of Ambiguous Lineage,  Not Otherwise Specified (NOS)||Disease||
 +
| ||JH / MS
 
|??
 
|??
 
|
 
|
Line 460: Line 541:  
|Disease
 
|Disease
 
|Kay Weng Choy + Greg Conboy (Monash Health)
 
|Kay Weng Choy + Greg Conboy (Monash Health)
 +
|
 
|JH / MS
 
|JH / MS
 
|Complete
 
|Complete
Line 468: Line 550:  
|Disease
 
|Disease
 
|Daynna Wolff+Jessica Snider (Path Resident)
 
|Daynna Wolff+Jessica Snider (Path Resident)
 +
|
 
|JH / MS
 
|JH / MS
 
|PENDING
 
|PENDING
Line 476: Line 559:  
|Disease
 
|Disease
 
|Daynna Wolff+ Paige Woodham (Path Resident)
 
|Daynna Wolff+ Paige Woodham (Path Resident)
 +
|
 
|JH / MS
 
|JH / MS
 
|PENDING
 
|PENDING
Line 481: Line 565:  
|NON-WHO ENTITY
 
|NON-WHO ENTITY
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| ||Yassmine Akkari (YA)
+
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
 +
| ||Yassmine Akkari (YA)
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''|| ||YA
+
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease|| ||YA
+
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
Line 502: Line 590:  
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
 +
|
 
|YA
 
|YA
 
|PENDING
 
|PENDING
Line 507: Line 596:  
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
Line 520: Line 611:     
Lisa Smith + Yassmine Akkari
 
Lisa Smith + Yassmine Akkari
 +
|
 
|YA
 
|YA
 
|Complete
 
|Complete
Line 525: Line 617:  
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
Line 536: Line 630:  
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma,  BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
 
|    B-Lymphoblastic Leukemia/Lymphoma,  BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
 +
|
 
|YA
 
|YA
 
|Complete
 
|Complete
Line 541: Line 636:  
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease|| ||YA
+
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| ||YA
+
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| ||YA
+
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|NK-Lymphoblastic Leukemia/Lymphoma||Disease|| ||YA
+
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
 +
| ||YA
 
|
 
|
 
|
 
|
Line 569: Line 669:  
|Disease
 
|Disease
 
|Helene Bruyere
 
|Helene Bruyere
 +
|
 
|YA
 
|YA
 
|PENDING
 
|PENDING
Line 574: Line 675:  
|NON-WHO ENTITY
 
|NON-WHO ENTITY
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP)
+
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
 +
| ||Snehal Patel (SP)
 
|
 
|
 
|
 
|
Line 585: Line 688:  
|-
 
|-
 
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Honey Reddi
 
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Honey Reddi
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 591: Line 695:  
|-
 
|-
 
|       Monoclonal B-cell  Lymphocytosis||Disease||Honey Reddi
 
|       Monoclonal B-cell  Lymphocytosis||Disease||Honey Reddi
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 597: Line 702:  
|-
 
|-
 
|B-cell Prolymphocytic Leukemia||Disease||Honey Reddi
 
|B-cell Prolymphocytic Leukemia||Disease||Honey Reddi
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 603: Line 709:  
|-
 
|-
 
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
 
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
 +
|
 
|SP
 
|SP
 
|Complete
 
|Complete
Line 609: Line 716:  
|-
 
|-
 
|Hairy Cell Leukemia||Disease||Snehal Patel
 
|Hairy Cell Leukemia||Disease||Snehal Patel
 +
|
 
|SP
 
|SP
 
|Complete
 
|Complete
Line 615: Line 723:  
|-
 
|-
 
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
 
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
 +
|
 
|SP
 
|SP
 
|Complete
 
|Complete
Line 621: Line 730:  
|-
 
|-
 
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
 
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
 +
|
 
|SP
 
|SP
 
|Complete
 
|Complete
Line 627: Line 737:  
|-
 
|-
 
|    Hairy Cell Leukemia  Variant||Disease||Snehal Patel
 
|    Hairy Cell Leukemia  Variant||Disease||Snehal Patel
 +
|
 
|SP
 
|SP
 
|Complete
 
|Complete
Line 633: Line 744:  
|-
 
|-
 
|Lymphoplasmacytic Lymphoma||Disease||Honey Reddi
 
|Lymphoplasmacytic Lymphoma||Disease||Honey Reddi
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 639: Line 751:  
|-
 
|-
 
|   Waldenstrom  Macroglobulinemia||Disease||Honey Reddi
 
|   Waldenstrom  Macroglobulinemia||Disease||Honey Reddi
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 644: Line 757:  
|
 
|
 
|-
 
|-
−
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| ||SP
+
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Heavy Chain Diseases'''''||'''''Overview'''''|| ||SP
+
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Mu Heavy Chain  Disease||Disease|| ||SP
+
|    Mu Heavy Chain  Disease||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   Gamma Heavy Chain  Disease||Disease|| ||SP
+
|   Gamma Heavy Chain  Disease||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Alpha Heavy Chain  Disease||Disease|| ||SP
+
|    Alpha Heavy Chain  Disease||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 670: Line 788:  
|-
 
|-
 
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
 
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 676: Line 795:  
|-
 
|-
 
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
 
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 682: Line 802:  
|-
 
|-
 
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
 
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 688: Line 809:  
|-
 
|-
 
|    Plasma Cell Myeloma  Variants||Disease||Zhenya Tang
 
|    Plasma Cell Myeloma  Variants||Disease||Zhenya Tang
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 694: Line 816:  
|-
 
|-
 
|    Plasmacytoma||Disease||Zhenya Tang
 
|    Plasmacytoma||Disease||Zhenya Tang
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 699: Line 822:  
|
 
|
 
|-
 
|-
−
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| ||SP
+
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|           Primary  Amyloidosis||Disease|| ||SP
+
|           Primary  Amyloidosis||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|           Light Chain  and Heavy Chain Deposition Disease||Disease|| ||SP
+
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| ||SP
+
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|         POEMS Syndrome||Disease|| ||SP
+
|         POEMS Syndrome||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|         TEMPI Syndrome||Disease|| ||SP
+
|         TEMPI Syndrome||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 730: Line 859:  
|-
 
|-
 
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease||Zhenya Tang & Trainee
 
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease||Zhenya Tang & Trainee
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 735: Line 865:  
|
 
|
 
|-
 
|-
−
|Nodal Marginal Zone Lymphoma||Disease|| ||SP
+
|Nodal Marginal Zone Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 741: Line 872:  
|-
 
|-
 
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
 
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 747: Line 879:  
|-
 
|-
 
|Follicular Lymphoma||Disease||Ruthann Pfau
 
|Follicular Lymphoma||Disease||Ruthann Pfau
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 753: Line 886:  
|-
 
|-
 
|    Testicular Follicular  Lymphoma||Disease||Ruthann Pfau
 
|    Testicular Follicular  Lymphoma||Disease||Ruthann Pfau
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 759: Line 893:  
|-
 
|-
 
|    In Situ Follicular  Neoplasia||Disease||Ruthann Pfau
 
|    In Situ Follicular  Neoplasia||Disease||Ruthann Pfau
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 765: Line 900:  
|-
 
|-
 
|    Duodenal-Type  Follicular Lymphoma||Disease||Ruthann Pfau
 
|    Duodenal-Type  Follicular Lymphoma||Disease||Ruthann Pfau
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 771: Line 907:  
|-
 
|-
 
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
 
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 776: Line 913:  
|
 
|
 
|-
 
|-
−
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| ||SP
+
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Primary Cutaneous Follicle Centre Lymphoma||Disease|| ||SP
+
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 787: Line 926:  
|-
 
|-
 
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
 
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
 +
|
 
|SP
 
|SP
 
|PENDING - due 8/15/20
 
|PENDING - due 8/15/20
Line 793: Line 933:  
|-
 
|-
 
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Mahsa Khanlari
 
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Mahsa Khanlari
 +
|
 
|SP
 
|SP
 
|PENDING - due 8/31/20
 
|PENDING - due 8/31/20
Line 799: Line 940:  
|-
 
|-
 
|    In Situ Mantle Cell  Neoplasia||Disease||Mahsa Khanlari
 
|    In Situ Mantle Cell  Neoplasia||Disease||Mahsa Khanlari
 +
|
 
|SP
 
|SP
 
|PENDING - due 8/15/20
 
|PENDING - due 8/15/20
Line 804: Line 946:  
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
Line 810: Line 953:  
|-
 
|-
 
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra
 
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra
 +
|
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 
|PENDING
 
|PENDING
Line 815: Line 959:  
|
 
|
 
|-
 
|-
−
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| ||GC
+
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| ||GC
+
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| ||GC
+
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease|| ||GC
+
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|EBV-Positive Mucocutaneous Ulcer||Disease|| ||GC
+
|EBV-Positive Mucocutaneous Ulcer||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease|| ||GC
+
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease|| ||GC
+
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Lymphomatoid Granulomatosis||Disease|| ||GC
+
|Lymphomatoid Granulomatosis||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| ||GC
+
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Intravascular Large B-cell Lymphoma||Disease|| ||GC
+
|Intravascular Large B-cell Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|ALK-Positive Large B-cell Lymphoma||Disease|| ||GC
+
|ALK-Positive Large B-cell Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera||GC
+
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
 +
| ||GC
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Primary Effusion Lymphoma||Disease|| ||GC
+
|Primary Effusion Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| ||GC
+
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   Multicentric Castleman  Disease||Disease|| ||GC
+
|   Multicentric Castleman  Disease||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC
+
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease|| ||GC
+
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Burkitt Lymphoma||Disease|| ||GC
+
|Burkitt Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Burkitt-Like Lymphoma with 11q Aberration||Disease|| ||GC
+
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| ||GC
+
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| ||GC
+
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC
+
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| ||GC
+
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
 +
| ||GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP)
+
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
 +
| ||Snehal Patel (SP)
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|T-cell Prolymphocytic Leukemia||Disease||Michelle Don||SP
+
|T-cell Prolymphocytic Leukemia||Disease||Michelle Don
 +
| ||SP
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don||SP
+
|T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
 +
| ||SP
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don||SP
+
|Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
 +
| ||SP
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Aggressive NK-cell Leukemia||Disease|| ||SP
+
|Aggressive NK-cell Leukemia||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''|| ||SP
+
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease|| ||SP
+
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease|| ||SP
+
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease|| ||SP
+
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Severe Mosquito Bite  Allergy||Disease|| ||SP
+
|    Severe Mosquito Bite  Allergy||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Adult T-cell Leukemia/Lymphoma||Disease|| ||SP
+
|Adult T-cell Leukemia/Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| ||SP
+
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 996: Line 1,176:  
|-
 
|-
 
|'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee)
 
|'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,002: Line 1,183:  
|-
 
|-
 
|     Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee)
 
|     Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,008: Line 1,190:  
|-
 
|-
 
|     Monomorphic  Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara
 
|     Monomorphic  Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,014: Line 1,197:  
|-
 
|-
 
|     Intestinal T-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee)
 
|     Intestinal T-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,020: Line 1,204:  
|-
 
|-
 
|    Indolent T-cell  Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee)
 
|    Indolent T-cell  Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,025: Line 1,210:  
|
 
|
 
|-
 
|-
−
|Hepatosplenic T-cell Lymphoma||Disease||Michelle Don||SP
+
|Hepatosplenic T-cell Lymphoma||Disease||Michelle Don
 +
| ||SP
 
|PENDING
 
|PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| ||SP
+
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mycosis Fungoides||Disease|| ||SP
+
|Mycosis Fungoides||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Sézary Syndrome||Disease|| ||SP
+
|Sézary Syndrome||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''|| ||SP
+
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Lymphomatoid  Papulosis||Disease|| ||SP
+
|    Lymphomatoid  Papulosis||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease|| ||SP
+
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| ||SP
+
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|     Primary Cutaneous  Gamma Delta T-cell Lymphoma||Disease|| ||SP
+
|     Primary Cutaneous  Gamma Delta T-cell Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|     Primary Cutaneous  CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| ||SP
+
|     Primary Cutaneous  CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|     Primary Cutaneous  Acral CD8+ T-cell Lymphoma||Disease|| ||SP
+
|     Primary Cutaneous  Acral CD8+ T-cell Lymphoma||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|     Primary Cutaneous  CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| ||SP
+
|     Primary Cutaneous  CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||SP
+
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''|| ||SP
+
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 1,096: Line 1,295:  
|-
 
|-
 
|     Angioimmunoblastic  T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
 
|     Angioimmunoblastic  T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,102: Line 1,302:  
|-
 
|-
 
|    Follicular T-cell  Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
 
|    Follicular T-cell  Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,107: Line 1,308:  
|
 
|
 
|-
 
|-
−
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| ||SP
+
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
 +
| ||SP
 
|
 
|
 
|
 
|
Line 1,113: Line 1,315:  
|-
 
|-
 
|Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara
 
|Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,119: Line 1,322:  
|-
 
|-
 
|Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara
 
|Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,125: Line 1,329:  
|-
 
|-
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara
 +
|
 
|SP
 
|SP
 
|PENDING
 
|PENDING
Line 1,130: Line 1,335:  
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| ||Associate Editor??
+
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
 +
| ||Associate Editor??
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| ||
+
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| ||
+
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease|| ||
+
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease|| ||
+
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Mixed Cellularity  Classic Hodgkin Lymphoma||Disease|| ||
+
|    Mixed Cellularity  Classic Hodgkin Lymphoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease|| ||
+
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| ||
+
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Lymphomas Associated with HIV Infection||Disease|| ||
+
|Lymphomas Associated with HIV Infection||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| ||
+
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Non-Destructive  Post-Transplant Lymphoproliferative Disorders||Disease|| ||
+
|    Non-Destructive  Post-Transplant Lymphoproliferative Disorders||Disease||
 +
| ||
 
|
 
|
 
|
 
|
Line 1,193: Line 1,410:     
Fabiola Quintero-Rivera
 
Fabiola Quintero-Rivera
 +
|
 
|
 
|
 
|PENDING
 
|PENDING
Line 1,198: Line 1,416:  
|
 
|
 
|-
 
|-
−
|'''''    Monomorphic  Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| ||
+
|'''''    Monomorphic  Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|          Monomorphic  B-cell PTLD||Disease|| ||
+
|          Monomorphic  B-cell PTLD||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|          Monomorphic  T/NK-cell PTLD||Disease|| ||
+
|          Monomorphic  T/NK-cell PTLD||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Classical Hodgkin  Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| ||
+
|    Classical Hodgkin  Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative  Disorders||Disease|| ||
+
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative  Disorders||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| ||
+
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Histiocytic Sarcoma||Disease|| ||
+
|Histiocytic Sarcoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| ||
+
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   Langerhans Cell  Histiocytosis||Disease|| ||
+
|   Langerhans Cell  Histiocytosis||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|   Langerhans Cell  Sarcoma||Disease|| ||
+
|   Langerhans Cell  Sarcoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Indeterminate Dendritic Cell Tumour||Disease|| ||
+
|Indeterminate Dendritic Cell Tumour||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Interdigitating Dendritic Cell Sarcoma||Disease|| ||
+
|Interdigitating Dendritic Cell Sarcoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Follicular Dendritic Cell Sarcoma||Disease|| ||
+
|Follicular Dendritic Cell Sarcoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|    Inflammatory  Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| ||
+
|    Inflammatory  Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Fibroblastic Reticular Cell Tumor||Disease|| ||
+
|Fibroblastic Reticular Cell Tumor||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Disseminated Juvenile Xanthogranuloma||Disease|| ||
+
|Disseminated Juvenile Xanthogranuloma||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Erdheim-Chester Disease||Disease|| ||
+
|Erdheim-Chester Disease||Disease||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
| || || ||
+
| || ||
 +
| ||
 
|
 
|
 
|
 
|
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/8655"